Drugs / PRTX007
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07565285 | Jul 2026 → Dec 2027 expected | melanoma | Primmune Therapeutics, Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRTX007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07565285 ↗ |
| Action | Activate | “a Toll-like receptor 7 (TLR7) agonist designed to activate innate and adaptive immune responses” NCT07565285 ↗ |
| Route | Oral | “Oral administration” NCT07565285 ↗ |
| Target | TLR7 | “Toll-like receptor 7 (TLR7) agonist” NCT07565285 ↗ |